With diabetes in India reaching epidemic proportions, the related therapeutics market is expected to grow at a double digit rate over the next 5 years. Higher disposable incomes have raised the incidence of this lifestyle disease, turning India into the world’s diabetic capital. Enhanced diagnostics will further broaden the patient base, and pharmaceutical companies that offer drugs with better efficacy and affordability will fare well in the market.
New analysis from Frost & Sullivan (healthcare.frost.com), Overview of the Diabetes Therapeutics Market in India, estimates the market revenues to reach $1.49 billion by 2016.
Rapid cultural changes, such as increasing urbanization, modified diet patterns, and sedentary lifestyles among the younger generation, have heightened the prevalence of diabetes in India. With a rapidly expanding segment of aging people, the treatment pool for type 2 cases in particular is expected to grow, increasing uptake of non-insulin therapies.
"The market for new non-insulin and insulin therapies is gaining ground, as treatment outcomes improve," said the Frost & Sullivan Analyst. "Novel drugs such as incretin mimetics, glucagon-like peptide-1 (GLP-1) agonists, and dipeptidyl peptidase-IV (DPP-IV) inhibitors are also earning acceptance among physicians."
The patent expiries of several existing drugs will actuate the launch of their generic versions. Although consumption volumes of these diabetes medications are expected to rise, their lower costs will not make significant impact on market revenues.
To boost the adoption of new drug classes, educational programs for both physicians and patients are necessary. Only a small percentage of the Indian population fully understands the disease, and government initiatives, such as the National Program for the Prevention and Control of Diabetes, Cardiovascular Diseases, and Stroke (NPDCS), aim to increase this percentage.
"The Indian government has also held mass early detection screening programs in 100 districts and 33 cities," noted the analyst. "Patient compliance centres are addressing the challenges of expensive treatment, inconvenient modes of administration, and the unpleasant side effects of oral anti-diabetics. These initiatives will result in better diabetes management and increase patient share, fuelling growth in the therapeutics market."
If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Caroline Lewis/ Akshata Mhatre, Corporate Communications, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.. Upon receipt of the above information, a brochure will be sent to you by email.
Overview of the Diabetes Therapeutics Market in India is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: Contract Research and Manufacturing Services Market in India, Clinical Research Organization Market in India, Vaccine Market in India and GCC Pharmaceutical Market, All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Overview of the Diabetes Therapeutics Market in India / P585-52
Corporate Communications – South Asia, Middle East and North Africa
P: +91 98200 50519 - E: niyer[.]frost.com.